Subscribe to RSS
DOI: 10.1055/a-2405-1909
The Implications of a “Flat” Oral Glucose Tolerance Test Curve in Pregnancy
Funding None.Abstract
Objective This study aimed to determine whether pregnant women who have “flat” oral glucose tolerance test (OGTT) curves in pregnancy are at increased risk of maternal or neonatal adverse outcomes.
Study Design We conducted a retrospective cohort study of the perinatal outcomes of pregnant women whose 100-g OGTT curve was “flat,” defined by a fasting serum glucose level below 95 mg/dL and the remaining values below 100 mg/dL. We compared their perinatal outcomes to women whose OGTT curve was “normal.” The primary outcomes compared were the prevalence of macrosomic and small for gestational age (SGA) neonates. Secondary outcomes included hypertensive disorders of pregnancy (HDP), prelabor anemia, thrombocytopenia, intrauterine fetal demise, placental abruption, indicated induction of labor, meconium-stained amniotic fluid, mode of delivery, postpartum hemorrhage, blood product transfusion, postpartum readmission, neonatal gender, gestational age at delivery, preterm birth, birth weight, low birth weight, umbilical artery pH < 7.1, Apgar score <7 at 5 minutes, neonatal intensive care unit admission, neonatal respiratory and infectious morbidity, and hypoglycemia. Composite adverse maternal and neonatal outcomes were also evaluated.
Results There were 1,060 patients in the study group and 10,591 patients in the control group. Patients with a flat OGTT were younger (28.3 vs. 29.8, p < 0.001) and less likely to be over 35 years old (14.1 vs. 23.4%, p < 0.001). They had a reduced risk of delivering a macrosomic neonate (11.4 vs. 15.1%, OR = 0.7 [0.58–0.89], p = 0.001) and having an unplanned cesarean delivery (7.5 vs. 10.2%, OR = 0.8 [0.58–0.96], p = 0.002). There was no difference in the rate of composite adverse maternal (14.0 vs. 15.4%, OR = 0.9 [0.7–1.0], p = 0.1) or neonatal outcome (5.3 vs. 4.5%, OR = 1.2 [0.9–1.5], p = 0.15). Neonates had a slightly lower mean birth weight (3,474 vs. 3,505 g, p = 0.04) but the rate of SGA was similar in the two groups (2.5 vs. 1.8%, OR = 1.3 [0.9–2.0], p = 0.08).
Conclusion Pregnant women whose OGTT curve is flat have a lower risk of delivering macrosomic neonates and undergoing unplanned cesarean delivery and are not at increased risk of adverse maternal or neonatal outcomes. More research is required to evaluate the relationship between different OGTT curves and the fetal growth rate.
Key Points
-
Patients with a “flat” OGTT have a reduced risk of macrosomia.
-
Patients with a “flat” OGTT have a reduced risk of cesarean delivery.
-
Patients with a “flat” OGTT are not at increased risk of growth restriction.
Keywords
oral glucose tolerance test - fetal growth - OGTT - growth restriction - macrosomia - placental insufficiencyEthical Approval
This study was approved by the local ethics review board.
Authors' Contributions
M.L.: project development, first draft manuscript writing, data analysis, review of the final version of the manuscript.
E.S.: data collection and review of the final version of the manuscript.
R.N.: project development and review of the final version of the manuscript.
A.M.: project development, review of the final version of the manuscript.
L.K.L.: project development, data collection, and review of the final version of the manuscript.
Publication History
Received: 07 May 2024
Accepted: 25 August 2024
Accepted Manuscript online:
29 August 2024
Article published online:
19 September 2024
© 2024. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Catalano PM, Roman-Drago NM, Amini SB, Sims EA. Longitudinal changes in body composition and energy balance in lean women with normal and abnormal glucose tolerance during pregnancy. Am J Obstet Gynecol 1998; 179 (01) 156-165
- 2 Behboudi-Gandevani S, Amiri M, Bidhendi Yarandi R, Ramezani Tehrani F. The impact of diagnostic criteria for gestational diabetes on its prevalence: a systematic review and meta-analysis. Diabetol Metab Syndr 2019; 11: 11
- 3 American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 190: Gestational diabetes mellitus. Obstet Gynecol 2018; 131 (02) e49-e64
- 4 Utzschneider KM, Younes N, Rasouli N. et al; GRADE Research Group. Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Res Care 2021; 9 (01) e002264
- 5 Langer O, Damus K, Maiman M, Divon M, Levy J, Bauman W. A link between relative hypoglycemia-hypoinsulinemia during oral glucose tolerance tests and intrauterine growth retardation. Am J Obstet Gynecol 1986; 155 (04) 711-716
- 6 Naeh A, Wilkof-Segev R, Jaffe A, Maor-Sagie E, Hallak M, Gabbay-Benziv R. Flat oral glucose tolerance test during pregnancy: maternal characteristics and risk for adverse outcomes. Clin Diabetes 2021; 39 (03) 313-319
- 7 Navon I, Romano A, Pardo A. et al. Flat maternal glucose response curve and adverse pregnancy outcome. J Perinatol 2023; 43 (09) 1101-1104
- 8 Valensise H, Romanini C. Second-trimester uterine artery flow velocity waveform and oral glucose tolerance test as a means of predicting intrauterine growth retardation. Ultrasound Obstet Gynecol 1993; 3 (06) 412-416
- 9 Rogne T, Jacobsen GW. Association between low blood glucose increase during glucose tolerance tests in pregnancy and impaired fetal growth. Acta Obstet Gynecol Scand 2014; 93 (11) 1160-1169
- 10 Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982; 144 (07) 768-773
- 11 Dollberg S, Haklai Z, Mimouni FB, Gorfein I, Gordon ES. Birth weight standards in the live-born population in Israel. Isr Med Assoc J 2005; 7 (05) 311-314
- 12 Contreras M, Sacks DA, Bowling F. et al. The Hyperglycemia and Adverse Pregnancy Outcome (Hapo) study. Int J Gynecol Obstet 2002; 78 (01) 69-77
- 13 Breschi MC, Seghieri G, Bartolomei G, Gironi A, Baldi S, Ferrannini E. Relation of birthweight to maternal plasma glucose and insulin concentrations during normal pregnancy. Diabetologia 1993; 36 (12) 1315-1321
- 14 Vadakekut ES, McCoy SJ, Payton ME. Association of maternal hypoglycemia with low birth weight and low placental weight: a retrospective investigation. J Am Osteopath Assoc 2011; 111 (03) 148-152
- 15 Shinohara S, Uchida Y, Hirai M, Hirata S, Suzuki K. Relationship between maternal hypoglycaemia and small-for-gestational-age infants according to maternal weight status: a retrospective cohort study in two hospitals. BMJ Open 2016; 6 (12) e013749
- 16 Calfee EF, Rust OA, Bofill JA, Ross EL, Morrison JC. Maternal hypoglycemia: is it associated with adverse perinatal outcome?. J Perinatol 1999; 19 (05) 379-382
- 17 Kim JY, Michaliszyn SF, Nasr A. et al. The shape of the glucose response curve during an oral glucose tolerance test heralds biomarkers of type 2 diabetes risk in obese youth. Diabetes Care 2016; 39 (08) 1431-1439
- 18 Holdsworth CD, Besser GM. Influence of gastric emptying-rate and of insulin response on oral glucose tolerance in thyroid disease. Lancet 1968; 2 (7570) 700-702
- 19 Pakhetra R, Garg MK, Saini JSIS. Is beta cell dysfunction responsible for flat glucose tolerance curve in primary hypothyroidism? (A hypothesis). Med J Armed Forces India 2001; 57 (02) 120-125
- 20 Szoke D, Robbiano C, Dolcini R. et al. Incidence and status of insulin secretion in pregnant women with flat plasma glucose profiles during oral glucose tolerance test. Clin Biochem 2022; 109–110: 23-27
- 21 McMaster-Fay RA. Intrauterine growth restriction: recent developments, definitions and future research. Clin Obstet Gynecol Reprod Med 2019; 5 (05) DOI: 10.15761/cogrm.1000266.
- 22 Khalil A, Thilaganathan B. Role of uteroplacental and fetal Doppler in identifying fetal growth restriction at term. Best Pract Res Clin Obstet Gynaecol 2017; 38: 38-47
- 23 Rial-Crestelo M, Lubusky M, Parra-Cordero M. et al; RATIO37 Study Group. Term planned delivery based on fetal growth assessment with or without the cerebroplacental ratio in low-risk pregnancies (RATIO37): an international, multicentre, open-label, randomised controlled trial. Lancet 2024; 403 (10426): 545-553
- 24 Yessoufou A, Moutaïrou K. Maternal diabetes in pregnancy: early and long-term outcomes on the offspring and the concept of “metabolic memory”. Exp Diabetes Res 2011; 2011: 218598
- 25 Hansen-Pupp I, Löfqvist C, Polberger S. et al. Influence of insulin-like growth factor I and nutrition during phases of postnatal growth in very preterm infants. Pediatr Res 2011; 69 (5 Pt 1): 448-453
- 26 Janssen AB, Capron LE, O'Donnell K. et al. Maternal prenatal depression is associated with decreased placental expression of the imprinted gene PEG3. Psychol Med 2016; 46 (14) 2999-3011
- 27 Enzi G, Inelmen EM, Caretta F, Rubaltelli F, Grella P, Baritussio A. Adipose tissue development “in utero”. Relationships between some nutritional and hormonal factors and body fat mass enlargement in newborns. Diabetologia 1980; 18 (02) 135-140
- 28 Männik J, Vaas P, Rull K, Teesalu P, Rebane T, Laan M. Differential expression profile of growth hormone/chorionic somatomammotropin genes in placenta of small- and large-for-gestational-age newborns. J Clin Endocrinol Metab 2010; 95 (05) 2433-2442
- 29 Jeckel KM, Boyarko AC, Bouma GJ, Winger QA, Anthony RV. Chorionic somatomammotropin impacts early fetal growth and placental gene expression. J Endocrinol 2018; 237 (03) 301-310
- 30 Houghton DJ, Shackleton P, Obiekwe BC, Chard T. Relationship of maternal and fetal levels of human placental lactogen to the weight and sex of the fetus. Placenta 1984; 5 (05) 455-458
- 31 Markestad T, Bergsjø P, Aakvaag A. et al. Prediction of fetal growth based on maternal serum concentrations of human chorionic gonadotropin, human placental lactogen and estriol. Acta Obstet Gynecol Scand Suppl 1997; 165: 50-55
- 32 Howell RJS, Perry LA, Choglay NS, Bohn H, Chard T. Placental protein 12 (PP12): a new test for the prediction of the small-for-gestational-age infant. Br J Obstet Gynaecol 1985; 92 (11) 1141-1144
- 33 Rassie KL, Giri R, Melder A, Joham A, Mousa A, Teede HJ. Lactogenic hormones in relation to maternal metabolic health in pregnancy and postpartum: protocol for a systematic review. BMJ Open 2022; 12 (02) e055257
- 34 Ishihara N, Matsuo H, Murakoshi H, Laoag-Fernandez JB, Samoto T, Maruo T. Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either preeclampsia or intrauterine growth retardation. Am J Obstet Gynecol 2002; 186 (01) 158-166
- 35 Maltepe E, Penn AA. Development, function, and pathology of the placenta. In: Gleason CA, Sawyer T. eds. Avery's Diseases of the Newborn. 11th ed.. Elsevier; 2024: 19-32.e7 . ISBN 9780323828239 DOI: 10.1016/B978-0-323-82823-9.00003-9
- 36 Klopper A. Fetal monitoring: biochemical methods. In: Whitte MJ. ed. Clinical Obstetrics Gynecology. London, Philadelphia: Baillier Tindal; 1987: 13
- 37 Granat M, Sharf M, Diengott D, Spindel A, Kahana L, Elrad H. Further investigation on the predictive value of human placental lactogen in high-risk pregnancies. Am J Obstet Gynecol 1977; 129 (06) 647-654
- 38 Letchworth AT, Slattery M, Dennis KJ. Clinical application of human-placental-lactogen values in late pregnancy. Lancet 1978; 1 (8071) 955-957
- 39 Spellacy WN, Buhi WC, Birk SA. Human placental lactogen and intrauterine growth retardation. Obstet Gynecol 1976; 47 (04) 446-448
- 40 Kelly AM, England P, Lorimer JD, Ferguson JC, Govan AD. An evaluation of human placental lactogen levels in hypertension of pregnancy. Br J Obstet Gynaecol 1975; 82 (04) 272-277
- 41 Lindberg BS, Nilsson BA. Human placental lactogen (HPL) levels in abnormal pregnancies. J Obstet Gynaecol Br Commonw 1973; 80 (12) 1046-1053
- 42 Sood R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human placenta. Proc Natl Acad Sci U S A 2006; 103 (14) 5478-5483
- 43 Edwards A, Megens A, Peek M, Wallace EM. Sexual origins of placental dysfunction. Lancet 2000; 355 (9199) 203-204
- 44 Murji A, Proctor LK, Paterson AD, Chitayat D, Weksberg R, Kingdom J. Male sex bias in placental dysfunction. Am J Med Genet A 2012; 158A (04) 779-783
- 45 Unterscheider J, O'Donoghue K, Daly S. et al. Fetal growth restriction and the risk of perinatal mortality-case studies from the multicentre PORTO study. BMC Pregnancy Childbirth 2014; 14 (01) 63